RU2096411C1 - Производные бензимидазолона, смеси их изомеров или их кислотно-аддитивные соли в качестве антагониста рецептора 5-ht*00i*00a и 5-нт*002 - Google Patents

Производные бензимидазолона, смеси их изомеров или их кислотно-аддитивные соли в качестве антагониста рецептора 5-ht*00i*00a и 5-нт*002 Download PDF

Info

Publication number
RU2096411C1
RU2096411C1 RU9294015171A RU94015171A RU2096411C1 RU 2096411 C1 RU2096411 C1 RU 2096411C1 RU 9294015171 A RU9294015171 A RU 9294015171A RU 94015171 A RU94015171 A RU 94015171A RU 2096411 C1 RU2096411 C1 RU 2096411C1
Authority
RU
Russia
Prior art keywords
carbon atoms
alkyl
dihydro
unsubstituted
benzimidazol
Prior art date
Application number
RU9294015171A
Other languages
English (en)
Russian (ru)
Other versions
RU94015171A (ru
Inventor
Биетти Джузеппе
Борсини Франко
Туркони Марио
Джиральдо Этторе
Бигнотти Марио
Original Assignee
Берингер Ингельхейм, Италиа, С.п.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Берингер Ингельхейм, Италиа, С.п.А. filed Critical Берингер Ингельхейм, Италиа, С.п.А.
Publication of RU94015171A publication Critical patent/RU94015171A/ru
Application granted granted Critical
Publication of RU2096411C1 publication Critical patent/RU2096411C1/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
RU9294015171A 1991-07-30 1992-07-30 Производные бензимидазолона, смеси их изомеров или их кислотно-аддитивные соли в качестве антагониста рецептора 5-ht*00i*00a и 5-нт*002 RU2096411C1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ITMI91A002118 1991-07-30
ITMI912118A IT1251144B (it) 1991-07-30 1991-07-30 Derivati del benzimidazolone
ITM191A002118 1991-07-30
PCT/IT1992/000088 WO1993003016A1 (en) 1991-07-30 1992-07-30 Benzimidazolone derivatives as 5-ht1a and 5-ht2 antagonists

Publications (2)

Publication Number Publication Date
RU94015171A RU94015171A (ru) 1995-09-10
RU2096411C1 true RU2096411C1 (ru) 1997-11-20

Family

ID=11360463

Family Applications (1)

Application Number Title Priority Date Filing Date
RU9294015171A RU2096411C1 (ru) 1991-07-30 1992-07-30 Производные бензимидазолона, смеси их изомеров или их кислотно-аддитивные соли в качестве антагониста рецептора 5-ht*00i*00a и 5-нт*002

Country Status (31)

Country Link
US (1) US5576318A (enExample)
EP (1) EP0526434B1 (enExample)
JP (1) JP2989667B2 (enExample)
KR (1) KR100263495B1 (enExample)
AT (1) ATE191910T1 (enExample)
AU (1) AU665366B2 (enExample)
CA (1) CA2114542C (enExample)
CZ (1) CZ281511B6 (enExample)
DE (1) DE69230926T2 (enExample)
DK (1) DK0526434T3 (enExample)
EE (1) EE03070B1 (enExample)
ES (1) ES2144412T3 (enExample)
FI (1) FI111460B (enExample)
GR (1) GR3033947T3 (enExample)
HU (2) HUT70195A (enExample)
IE (1) IE922464A1 (enExample)
IL (1) IL102665A (enExample)
IT (1) IT1251144B (enExample)
MX (1) MX9204139A (enExample)
NO (1) NO304070B1 (enExample)
NZ (1) NZ243777A (enExample)
PH (1) PH30998A (enExample)
PL (1) PL171329B1 (enExample)
PT (1) PT526434E (enExample)
RU (1) RU2096411C1 (enExample)
SG (1) SG52407A1 (enExample)
SK (1) SK279292B6 (enExample)
TW (1) TW209862B (enExample)
UA (1) UA42684C2 (enExample)
WO (1) WO1993003016A1 (enExample)
ZA (1) ZA925682B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2415138C2 (ru) * 2005-07-13 2011-03-27 Ф. Хоффманн-Ля Рош Аг Производные бензимидазола и индола в качестве селективных антагонистов 5-нт6 и/или 5-нт2а рецепторов

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1251144B (it) * 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone
US5266571A (en) * 1992-01-09 1993-11-30 Amer Moh Samir Treatment of hemorrhoids with 5-HT2 antagonists
SE9201138D0 (sv) * 1992-04-09 1992-04-09 Astra Ab Novel phthalimidoalkylpiperazines
DK148392D0 (da) * 1992-12-09 1992-12-09 Lundbeck & Co As H Heterocykliske forbindelser
CA2158457C (en) * 1993-03-16 2001-04-17 Bertrand Leo Chenard Naphthalene derivatives
JP3719612B2 (ja) * 1993-06-14 2005-11-24 塩野義製薬株式会社 ヘテロ環を含有する尿素誘導体
IL114027A (en) 1994-06-08 1999-11-30 Lundbeck & Co As H 4-Phenyl piperazine (piperidine or tetrahydropyridine) derivatives serotinin 5-HT1A and dopamin D2 receptor ligand pharmaceutical compositions containing them
DE69523155T2 (de) * 1994-06-14 2002-02-07 Pfizer Inc., New York Benzimidazolonderivate mit zentraler dopaminerger aktivität
PT775118E (pt) * 1994-08-05 2003-10-31 Pfizer Derivados de benzimidazole com actividade dopaminergica
US5883094A (en) * 1995-04-24 1999-03-16 Pfizer Inc. Benzimidazolone derivatives with central dopaminergic activity
US5889010A (en) * 1995-05-18 1999-03-30 Pfizer Inc. Benzimidazole derivatives having dopaminergic activity
WO1997016187A1 (en) * 1995-10-31 1997-05-09 Merck & Co., Inc. Muscarine antagonists
CN1312802A (zh) * 1998-06-15 2001-09-12 美国家用产品公司 作为5－羟色胺能药物的环烷基取代的芳基哌嗪、哌啶和四氢吡啶
US6376494B1 (en) 1998-06-15 2002-04-23 American Home Products Corporation Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents
AR022303A1 (es) * 1999-01-22 2002-09-04 Lundbeck & Co As H Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion
IT1313625B1 (it) * 1999-09-22 2002-09-09 Boehringer Ingelheim Italia Derivati benzimidazolonici aventi affinita' mista per i recettori diserotonina e dopamina.
US6521623B1 (en) 2000-09-19 2003-02-18 Boehringer Ingelheim Pharma Kg N,N'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors
AU2001293804A1 (en) * 2000-09-19 2002-04-02 Boehringer Ingelheim Pharma Kg New benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors
US6586435B2 (en) 2000-09-19 2003-07-01 Boehringer Ingelheim Pharma Kg Benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors
AU2002223528A1 (en) * 2000-09-19 2002-04-02 Boeringer Ingelheim Pharma Gmbh & Co. Kg New n, n'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors
DK1408976T5 (da) * 2001-07-20 2011-01-10 Psychogenics Inc Behandling af ADHD (Attention deficit hyperactivity disorder)
US7183410B2 (en) 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
DK1414816T3 (da) * 2001-08-02 2005-04-11 Bidachem Spa Stabil polymorf af flibanserin, teknisk fremgangsmåde til fremstilling deraf og anvendelse deraf til lægemiddelfremstilling
DE10138273A1 (de) * 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Arzneimittel mit neuroprotektiver Wirkung
US20030060475A1 (en) * 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
US20040048877A1 (en) * 2002-05-22 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions containing flibanserin
HRP20041092B1 (hr) * 2002-05-22 2013-05-31 Boehringer Ingelheim Pharma Gmbh & Co.Kg Novi farmaceutski pripravci flibanserina
OA12923A (en) * 2002-09-17 2006-10-13 Warner Lambert Co Heterocyclic substituted piperazines for the treatment of schizophrenia.
ATE539077T1 (de) * 2003-09-03 2012-01-15 Pfizer Benzimidazolonverbindungen mit agonistischer wirkung am 5-ht4 rezeptor
AR045843A1 (es) * 2003-10-03 2005-11-16 Solvay Pharm Bv Derivados de bencimidazolonas y quinazolinonas sustituidas con hidronopol como agonistas en receptores orl 1 humanos
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
MXPA06012059A (es) * 2004-04-22 2007-01-25 Boehringer Ingelheim Int Nuevas composiciones farmaceuticas para el tratamiento de los trastornos sexuales ii.
US7737163B2 (en) * 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
BRPI0512046A (pt) * 2004-06-15 2008-02-06 Pfizer derivados de ácido benzimidazolona carboxìlico
US20060014757A1 (en) * 2004-07-14 2006-01-19 Boehringer Ingelheim Pharmaceuticals Method for the treatment of anorexia nervosa
US20060025420A1 (en) * 2004-07-30 2006-02-02 Boehringer Ingelheimn International GmbH Pharmaceutical compositions for the treatment of female sexual disorders
EP1789048A1 (en) * 2004-09-03 2007-05-30 Boehringer Ingelheim International GmbH Method for the treatment of attention deficit hyperactivity disorder
NZ556627A (en) * 2005-02-22 2010-09-30 Pfizer Oxyindole derivatives as 5HT4 receptor agonists
EP1858516A1 (en) * 2005-03-04 2007-11-28 Boehringer Ingelheim International GmbH Pharmaceutical compositions for the treatment and/or prevention of depression
US20060199805A1 (en) * 2005-03-04 2006-09-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
EP1904182A2 (en) * 2005-05-06 2008-04-02 Boehringer Ingelheim International GmbH Method for the treatment of drug abuse with flibanserin
JP2008540672A (ja) * 2005-05-19 2008-11-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 病状に起因する性的機能不全の治療方法
CA2608363A1 (en) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of drug-induced sexual dysfunction
US8227476B2 (en) 2005-08-03 2012-07-24 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
US7790726B2 (en) * 2005-08-16 2010-09-07 Chemocentryx, Inc. Monocyclic and bicyclic compounds and methods of use
CA2626134C (en) 2005-10-29 2013-12-24 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070123540A1 (en) * 2005-10-29 2007-05-31 Angelo Ceci Sexual desire enhancing medicaments comprising benzimidazolone derivatives
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
EP1988897A1 (en) * 2006-02-20 2008-11-12 Boehringer Ingelheim International GmbH Benzimidazolone derivatives for the treatment of urinary incontinence
EP2520567A3 (en) * 2006-02-23 2012-12-12 Shionogi & Co., Ltd. Nitrogen-containing heterocycle derivatives substituted with cyclic group
EP1991228A1 (en) * 2006-02-28 2008-11-19 Boehringer Ingelheim International GmbH Treatment of prevention of valvular heart disease with flibanserin
JP2009536176A (ja) * 2006-05-09 2009-10-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 閉経後の性的欲求障害の治療のためのフリバンセリンの使用
US20090312242A1 (en) * 2006-06-30 2009-12-17 Ramiro Castro Flibanserin for the treatment of urinary incontinence and related diseases
US20090318469A1 (en) * 2006-07-14 2009-12-24 Boehringer Ingelheim International Gmbh Use of Flibanserin for the Treatment of Sexual Disorders in Females
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
CA2660476C (en) 2006-08-14 2015-11-17 Boehringer Ingelheim International Gmbh Formulations of flibanserin and method for manufacturing the same
EP2056797A2 (en) 2006-08-25 2009-05-13 Boehringer Ingelheim International GmbH Controlled release system and method for manufacturing the same
US8722682B2 (en) 2006-12-20 2014-05-13 Sprout Pharmaceuticals, Inc. Sulfated benzimidazolone derivatives having mixed serotonin receptor affinity
US8304601B2 (en) * 2007-01-23 2012-11-06 Keiko Fujikawa Mouse model for eye disease
WO2008140239A1 (en) * 2007-05-11 2008-11-20 Korea Research Institute Of Chemical Technology Imidazole derivatives having aryl piperidine substituent, method for preparation thereof and pharmaceutical compositions containing same
PE20091188A1 (es) * 2007-09-12 2009-08-31 Boehringer Ingelheim Int Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen
EP2238117A1 (en) * 2008-01-24 2010-10-13 NeuroSearch A/S 4-phenyl-piperazin-1-yl-alkyl-benzoimidazol-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
EP2090297A1 (en) 2008-02-13 2009-08-19 Boehringer Ingelheim International GmbH Formulations of flibanserin
CA2686480A1 (en) * 2008-12-15 2010-06-15 Boehringer Ingelheim International Gmbh New salts
WO2010146595A2 (en) * 2009-06-16 2010-12-23 Symed Labs Limited Novel polymorphs of flibanserin hydrochloride
BRPI1003506B1 (pt) 2010-09-24 2019-12-03 Ache Int Bvi Ltd composto alquil-piperazino-fenil-4(3h)quinazolinonas e uso do composto alquil-piperazino-fenil-4(3h)quinazolinonas associado aos receptores serotoninérgicos 5-ht1a e 5-ht2a
AU2013329097B2 (en) * 2012-10-11 2018-10-18 Southern Research Institute Urea and amide derivatives of aminoalkylpiperazines and use thereof
CN104926734B (zh) * 2015-07-07 2017-04-05 苏州立新制药有限公司 氟班色林的制备方法
WO2017076213A1 (zh) * 2015-11-02 2017-05-11 苏州旺山旺水生物医药有限公司 苯并咪唑类化合物、其制备方法及用途
WO2017076356A1 (zh) * 2015-11-05 2017-05-11 苏州晶云药物科技有限公司 氟班色林的新晶型及其制备方法
CN106749038A (zh) * 2015-11-25 2017-05-31 山东诚创医药技术开发有限公司 一种氟班色林的制备方法
CN106866546A (zh) * 2015-12-10 2017-06-20 常州爱诺新睿医药技术有限公司 氟班色林或其药学上可接受的盐与药用辅料的固体分散体及其制备方法
WO2017128932A1 (zh) 2016-01-31 2017-08-03 孟晓明 氟班色林的新晶型及其制备方法及其用途
WO2017133337A1 (zh) * 2016-02-02 2017-08-10 深圳市塔吉瑞生物医药有限公司 一种取代的苯并咪唑酮化合物及包含该化合物的组合物
CN107235913B (zh) * 2016-03-29 2020-07-10 苏州科伦药物研究有限公司 工业规模高效制造优质氟班色林的方法
CN106866582A (zh) * 2017-01-10 2017-06-20 广州隽沐生物科技有限公司 一种氟班色林中间体的制备方法
HU231283B1 (hu) 2018-08-01 2022-09-28 Richter Gedeon Nyrt Eljárás a flibanserin többlépéses folyamatos áramú előállítására
CA3211341A1 (en) * 2021-03-19 2022-09-22 Centre National De La Recherche Scientifique Applications of biased ligands of the serotonin 5-ht7 receptor for the treatment of pain, multiple sclerosis and the control of thermoregulation

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3406178A (en) * 1964-02-04 1968-10-15 Monsanto Chem Australia Ltd Preparation of 2-substituted benzimidazoles
US3362956A (en) * 1965-08-19 1968-01-09 Sterling Drug Inc 1-[(heterocyclyl)-lower-alkyl]-4-substituted-piperazines
YU39992B (en) * 1976-04-02 1985-06-30 Janssen Pharmaceutica Nv Process for obtaining new piperazine and piperidine derivatives
FI791926A7 (fi) * 1978-06-20 1979-12-21 Synthelabo Fenylpiperazinderivat
IT1176613B (it) * 1984-08-14 1987-08-18 Ravizza Spa Derivati piperazinici farmacologicamente attivi e processo per la loro preparazione
IE58370B1 (en) * 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
GB8607294D0 (en) * 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
NL8601494A (nl) * 1985-06-22 1987-01-16 Sandoz Ag Thiazolen, hun bereiding en farmaceutische preparaten die ze bevatten.
GB8601160D0 (en) * 1986-01-17 1986-02-19 Fujisawa Pharmaceutical Co Heterocyclic compounds
US5036088A (en) * 1986-06-09 1991-07-30 Pfizer Inc. Antiallergy and antiinflammatory agents, compositions and use
JPH0784462B2 (ja) * 1986-07-25 1995-09-13 日清製粉株式会社 ベンゾイミダゾ−ル誘導体
US4954503A (en) * 1989-09-11 1990-09-04 Hoechst-Roussel Pharmaceuticals, Inc. 3-(1-substituted-4-piperazinyl)-1H-indazoles
IT1251144B (it) * 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GB, патент, 2023594, кл. C 07 D 401/06, 1980. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2415138C2 (ru) * 2005-07-13 2011-03-27 Ф. Хоффманн-Ля Рош Аг Производные бензимидазола и индола в качестве селективных антагонистов 5-нт6 и/или 5-нт2а рецепторов

Also Published As

Publication number Publication date
ITMI912118A0 (it) 1991-07-30
EP0526434A1 (en) 1993-02-03
ES2144412T3 (es) 2000-06-16
SK10194A3 (en) 1994-12-07
HK1010725A1 (en) 1999-06-25
MX9204139A (es) 1993-01-01
HUT70195A (en) 1995-09-28
IL102665A (en) 1996-10-31
HU211256A9 (en) 1995-11-28
CA2114542A1 (en) 1993-02-18
NZ243777A (en) 1995-04-27
KR100263495B1 (ko) 2000-11-01
FI111460B (fi) 2003-07-31
TW209862B (enExample) 1993-07-21
PT526434E (pt) 2000-08-31
DK0526434T3 (da) 2000-07-17
CZ17094A3 (en) 1994-05-18
CZ281511B6 (cs) 1996-10-16
NO940306D0 (no) 1994-01-28
PH30998A (en) 1997-12-23
WO1993003016A1 (en) 1993-02-18
HU9400255D0 (en) 1994-05-30
DE69230926D1 (de) 2000-05-25
NO304070B1 (no) 1998-10-19
IE922464A1 (en) 1993-02-10
JPH06509575A (ja) 1994-10-27
GR3033947T3 (en) 2000-11-30
AU665366B2 (en) 1996-01-04
PL302163A1 (en) 1994-07-11
CA2114542C (en) 2004-02-24
UA42684C2 (uk) 2001-11-15
IT1251144B (it) 1995-05-04
ATE191910T1 (de) 2000-05-15
AU2427592A (en) 1993-03-02
ITMI912118A1 (it) 1993-01-31
DE69230926T2 (de) 2000-10-05
EE03070B1 (et) 1998-02-16
PL171329B1 (pl) 1997-04-30
NO940306L (no) 1994-03-14
SK279292B6 (sk) 1998-09-09
FI940420A0 (fi) 1994-01-28
FI940420A7 (fi) 1994-01-28
US5576318A (en) 1996-11-19
JP2989667B2 (ja) 1999-12-13
ZA925682B (en) 1994-01-31
SG52407A1 (en) 1998-09-28
EP0526434B1 (en) 2000-04-19

Similar Documents

Publication Publication Date Title
RU2096411C1 (ru) Производные бензимидазолона, смеси их изомеров или их кислотно-аддитивные соли в качестве антагониста рецептора 5-ht*00i*00a и 5-нт*002
US4423049A (en) 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines
CN1034503C (zh) 吡唑并嘧啶酮抗心绞痛剂的制备方法
EP0748800B1 (en) Pyrimidinedione, pyrimidinetrione, triazinedione derivatives as alpha-1-adrenergic receptor antagonists
US4524206A (en) 1-Heteroaryl-4-(2,5-pyrrolidinedion-1-yl)alkyl)piperazine derivatives
JPH0314563A (ja) 新規４―フルオロ安息香酸誘導体
CA2684563C (en) 2-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-3-phenyl pyrazines and pyridines and 3-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-2-phenyl pyridines as 5-ht7 receptor antagonists
US5128343A (en) Derivatives of pyrimidinyl-piperazinyl-alkyl azoles with anxiolytic and/or tranquilizing activity
US4517188A (en) 1-Pyrimidinyloxy-3-hetaryl-alkylamino-2-propanols
SE465928B (sv) 1,2,4-triazolonfoereningar med antidepressiv aktivitet, foerfarande foer framstaellning av dessa och en farmaceutisk komposition
JP3805360B2 (ja) α▲下２Ａ▼アドレナリン受容体作動剤としての芳香族２−アミノ−イミダゾール誘導体
JPH07188207A (ja) １−［２ｈ−１−ベンゾピラン−２−オン−８−イル］−ピペラジン誘導体
HU201057B (en) Process for producing 6-phenyl-3-(piperazinyl-alkyl)-1h,3h-pyrimidin-2,4-dion derivatives and pharmaceutical compositions containing them
CZ299257B6 (cs) Zpusob výroby morfolinových derivátu
EP0594883B1 (en) Imidazo(1,2-c) quinazoline derivatives as antihypertensives and anti dysurics
JPH05221989A (ja) 複素環式化合物
JPH07258233A (ja) 新規な、アミノアルキルベンゾオキサゾリノン及びベンゾチアゾリノン、それらの製造方法及びそれらを含有する製薬学的組成物
FR2744451A1 (fr) Nouvelles imidazolidinones, pyrimidinones, et 1,3-diazepin-2 -ones, leur preparation et leurs applications en therapeutique
CS202069B2 (en) Method of preparing 2-/4-substituted piperazine-1-yl/-4-amino-6,7-dimethoxyquinazolines
CH681300A5 (enExample)
DE69431441T2 (de) Trizyklische verbindungen mit affinität für den 5-ht1a rezeptor
FR2540499A1 (fr) Derive de 5-fluoro-pyrimidine-2-yl piperazine antipsychotique
Gueremy et al. 4-Amino-6-chloro-2-piperazinopyrimidines with selective affinity for. alpha. 2-adrenoceptors
US5420130A (en) 2-aminopyrazine-5-carboxamide derivatives, their preparation and their application in therapeutics
KR19980081366A (ko) 신규한 나프틸피페라진 유도체